Pablo García‐Sanz

595 citations
12 papers · 387 indexed · h-index 11
Topics
Endometrial and Cervical Cancer Treatments (3 papers)Ubiquitin and proteasome pathways (3 papers)Ovarian cancer diagnosis and treatment (2 papers)
Partner nations
SpainPolandUnited States

In The Last Decade

Pablo García‐Sanz

12 papers receiving 383 citations

Peers

Pablo García‐Sanz
Comparison fields: 5 of 56
  • Molecular Biology 272
  • Cancer Research 85
  • Immunology 83
  • Pulmonary and Respiratory Medicine 63
  • Oncology 62
Replace Xiao Lv with:
Xiao Lv China
Michael WY Chan Taiwan
Minjia Sheng China
Mariko Sasaki Japan
Changxia Shao United States
Ziyang Di China
Emilie Marion Canuto Italy
Miyuki Kurai Japan
Yuexin Hu China
Chunfang Ha China
Pablo García‐Sanz relative to Xiao Lv China Xiao Lv's profile →
Citations per field
00.5×
Xiao Lv · 1×
Citations per year

Countries citing papers authored by Pablo García‐Sanz

Since Specialization
Citations

This map shows the geographic impact of Pablo García‐Sanz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo García‐Sanz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo García‐Sanz more than expected).

Fields of papers citing papers by Pablo García‐Sanz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo García‐Sanz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo García‐Sanz. The network helps show where Pablo García‐Sanz may publish in the future.

Co-authorship network of co-authors of Pablo García‐Sanz

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo García‐Sanz. A scholar is included among the top collaborators of Pablo García‐Sanz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo García‐Sanz. Pablo García‐Sanz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 13
2 8
3 19
4 33
5 30
6 23
7 17
8 154
9 26
10 16
11 21
12 27

About Pablo García‐Sanz

Pablo García‐Sanz is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Aquatic Science, having authored 12 papers that have together received 387 indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (3 papers), Ubiquitin and proteasome pathways (3 papers) and Ovarian cancer diagnosis and treatment (2 papers). The work is most often cited by research in Nephrology (41 citations), Cancer Research (85 citations) and Obstetrics and Gynecology (37 citations). Pablo García‐Sanz has collaborated with scholars based in Spain, Poland and United States. Frequent co-authors include Gema Moreno‐Bueno, Alejandro Rojo‐Sebastián, Alba Mota, Marta Hergueta‐Redondo, Saleta Morales, David Sarrió, Ángela Molina-Crespo, Héctor Peinado, Diego Megı́as and Amparo Cano. Their work appears in journals such as Journal of Biological Chemistry, PLoS ONE and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026